Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566) announced a plan to repurchase up to 10,909,678 H Shares in the open market. The share repurchase is funded with up to RMB100 million and will be conducted at prices not exceeding 5% above the five-day average closing price prior to each purchase. The repurchase mandate, approved at the 2024 annual general meeting on June 11, 2025, allows repurchases of up to 10% of the total number of H Shares in issue as of that date.
The repurchased shares may be canceled, held as treasury shares, or allocated to the company’s share incentive scheme. The board views the current share price as a potential undervaluation of Jiuyuan Genetic (2566)’s fundamentals and business prospects. The company maintains a stable financial position and believes its cash flows can support ongoing operational needs alongside the repurchase plan.
The plan will remain in effect until the conclusion of the next annual general meeting or until the repurchase mandate is revoked or varied, whichever is earlier. Jiuyuan Genetic (2566) emphasized that actual execution of the repurchase will depend on market conditions and no assurance is given regarding the timing, volume, or pricing of any share buyback. Interested parties are advised to note all relevant regulations and proceed with caution when dealing in the company’s shares.
Comments